Comparison of the effect of intravenous dexamethasone and methylprednisolone on the treatment of hospitalized patients with COVID-19: a randomized clinical trial.
Int J Infect Dis
; 122: 659-664, 2022 Sep.
Article
in English
| MEDLINE | ID: covidwho-2015434
ABSTRACT
OBJECTIVE:
In this study, we aimed to compare the effects of intravenous dexamethasone and methylprednisolone on the treatment of inpatients with COVID-19.METHODS:
In this randomized clinical trial, 143 patients under 80 years of age with moderate to severe COVID-19 were enrolled and randomly assigned to two groups dexamethasone (8 mg/day) and methylprednisolone (60 mg/day in two divided doses). The primary outcome was the length of hospital stay. The secondary outcomes included duration of oxygen therapy, absolute leukocyte and lymphocyte count, hypokalemia, hyperglycemia, intensive care unit admission, and mortality in the two groups for 28 days. Data were analyzed by SPSS version 26 using t-test, chi-square, and analysis of variance.RESULTS:
The duration of hospitalization was significantly (P <0.001) shorter in the dexamethasone group than in the methylprednisolone group (8 [95% confidence interval [CI]6-10] and 11 [95% CI 7-14], respectively). In addition, the duration of oxygen therapy in the dexamethasone group (7 [95% CI 5-9]) was significantly (P <0.001) shorter than in the methylprednisolone group (10 [95% CI 5.5-14]). The mortality rate was 17.1% (95% CI 8.1-26.1) in the dexamethasone group and 12.3% (95% CI 4.6-20.0) in the methylprednisolone group, which was not statistically significant (P = 0.46).CONCLUSION:
Results showed better effectiveness of 8 mg/day dexamethasone compared with 60 mg/day methylprednisolone based on the shorter hospital stay, which can be considered in the therapeutic protocol of COVID-19. TRIAL REGISTRATION IRCT20210223050466N1.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Int J Infect Dis
Journal subject:
Communicable Diseases
Year:
2022
Document Type:
Article
Affiliation country:
J.ijid.2022.07.019
Similar
MEDLINE
...
LILACS
LIS